Buyout Offer for Micromet Triggers Shareholder-Claim Investigation by Goldfarb LLP Securities Attorneys
DALLAS, Feb. 3, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating whether certain officers and directors of Micromet, Inc. (NASDAQ: MITI) violated shareholder protection laws by agreeing to a tender offer for $11.00 per share to Amgen. Concerned Micromet investors are encouraged to contact securities class action attorney Hamilton Lindley at 877-583-2855 or email@example.com about their rights and remedies for this potentially low buyout.
"The Wall Street Journal reported that Micromet and Amgen had a collaboration agreement to develop oncology drugs months ago," said Hamilton Lindley. "This buyout appears to be designed for Amgen to take advantage of a pipeline for a leukemia drug so that it can obtain the benefit, to the detriment of the Micromet stockholders. Our proposed shareholder lawsuit seeks to obtain a higher value for shareholders than the current buyout offer."
Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Micromet stockholders or anyone with knowledge about this acquisition should contact lawyer Hamilton Lindley at firstname.lastname@example.org or 877-583-2855 with questions or concerns.
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
SOURCE Goldfarb LLP